Decreased serum human leukocyte antigen‐G levels are associated with gestational diabetes mellitus

Author(s):  
Ozer Oztekin ◽  
Umit Cabus ◽  
Yasar Enli
2020 ◽  
Vol 32 (1) ◽  
Author(s):  
Muhamad R. Abdel Hameed ◽  
Osama Ahmed Ibrahiem ◽  
Entsar Hamed Ahmed ◽  
Paula Rofaeel Sedky ◽  
Naglaa Mohamed M. A. Mousa

Abstract Background Gestational diabetes mellitus is any degree of glucose intolerance with onset or first recognition occurring late in second trimester and third trimester of pregnancy. It constitutes a greater impact on diabetes epidemic as it carries a major risk for developing type 2 diabetes mellitus to the mother and her fetus later in life. human leukocyte antigen (HLA)-G is a class Ib gene presents in the human major histocompatibility complex (MHC). HLA-G has an important role for mother and fetus tolerance during pregnancy, also in the pancreatic islet cells protection. This is a case-control study, measuring serum HLA-G levels by ELISA in 60 pregnant women with gestational diabetes compared with 36 normal pregnant women. Results HLA-G levels were significantly high in pregnant women with gestational diabetes mellitus (GDM) in contrast to women with normal pregnancy (P = 0.001). Conclusion Women with GDM had significantly higher levels of soluble HLA-G than women without GDM, suggesting that HLA-G molecule is among the factors for regulation and control of the immune response and the induction of tolerance. Soluble HLA-G could be considered an important follow-up investigation for all pregnant primary health care for early detection of gestational diabetes.


2008 ◽  
Vol 69 (1) ◽  
pp. 9-15 ◽  
Author(s):  
Silvia Rosado ◽  
Gema Perez-Chacon ◽  
Susana Mellor-Pita ◽  
Inmaculada Sanchez-Vegazo ◽  
Carmen Bellas-Menendez ◽  
...  

2018 ◽  
Vol 8 (1) ◽  
Author(s):  
Roberta Rizzo ◽  
Maria D’Accolti ◽  
Daria Bortolotti ◽  
Francesca Caccuri ◽  
Arnaldo Caruso ◽  
...  

2021 ◽  
Vol 9 (10) ◽  
pp. e003050
Author(s):  
Chia-Ing Jan ◽  
Shi-Wei Huang ◽  
Peter Canoll ◽  
Jeffrey N Bruce ◽  
Yu-Chuan Lin ◽  
...  

BackgroundImmunotherapy against solid tumors has long been hampered by the development of immunosuppressive tumor microenvironment, and the lack of a specific tumor-associated antigen that could be targeted in different kinds of solid tumors. Human leukocyte antigen G (HLA-G) is an immune checkpoint protein (ICP) that is neoexpressed in most tumor cells as a way to evade immune attack and has been recently demonstrated as a useful target for chimeric antigen receptor (CAR)-T therapy of leukemia by in vitro studies. Here, we design and test for targeting HLA-G in solid tumors using a CAR strategy.MethodsWe developed a novel CAR strategy using natural killer (NK) cell as effector cells, featuring enhanced cytolytic effect via DAP12-based intracellular signal amplification. A single-chain variable fragment (scFv) against HLA-G is designed as the targeting moiety, and the construct is tested both in vitro and in vivo on four different solid tumor models. We also evaluated the synergy of this anti-HLA-G CAR-NK strategy with low-dose chemotherapy as combination therapy.ResultsHLA-G CAR-transduced NK cells present effective cytolysis of breast, brain, pancreatic, and ovarian cancer cells in vitro, as well as reduced xenograft tumor growth with extended median survival in orthotopic mouse models. In tumor coculture assays, the anti-HLA-G scFv moiety promotes Syk/Zap70 activation of NK cells, suggesting reversal of the HLA-G-mediated immunosuppression and hence restoration of native NK cytolytic functions. Tumor expression of HLA-G can be further induced using low-dose chemotherapy, which when combined with anti-HLA-G CAR-NK results in extensive tumor ablation both in vitro and in vivo. This upregulation of tumor HLA-G involves inhibition of DNMT1 and demethylation of transporter associated with antigen processing 1 promoter.ConclusionsOur novel CAR-NK strategy exploits the dual nature of HLA-G as both a tumor-associated neoantigen and an ICP to counteract tumor spread. Further ablation of tumors can be boosted when combined with administration of chemotherapeutic agents in clinical use. The readiness of this novel strategy envisions a wide applicability in treating solid tumors.


2013 ◽  
Vol 74 (3) ◽  
pp. 318-324 ◽  
Author(s):  
R.M. Blanco-García ◽  
M.R. López-Álvarez ◽  
I.P. Garrido ◽  
G. Salgado-Cecilia ◽  
J.A. Campillo ◽  
...  

2009 ◽  
Vol 16 (11) ◽  
pp. 1103-1111 ◽  
Author(s):  
Yong Wook Jung ◽  
Young Tae Kim ◽  
Sang Wun Kim ◽  
Sunghoon Kim ◽  
Jae Hoon Kim ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document